Oct 4, 2023

Medtronic names Paolo Di Vincenzo president of the Neuromodulation business

Medtronic plc (NYSE:MDT), the global leader in healthcare technology, is pleased to share that Paolo Di Vincenzo will join the company as president of the Neuromodulation business, effective Oct. 30. In this role, Di Vincenzo will be responsible for the overall strategic direction of the Medtronic Neuromodulation business and its day-to-day operations.

Di Vincenzo will join Medtronic from Smith+Nephew, where he was senior vice president and general manager, U.S., Advanced Wound Management. During his nine-year tenure with the company, he also served in global marketing and leadership roles. Prior to Smith+Nephew, Di Vincenzo held various marketing leadership roles of increasing responsibility at Systagenix (then Acelity), Becton Dickinson, and Roche Diagnostics.

“Paolo is a results-driven leader who puts people first,” said Brett Wall, executive vice president and president, Neurosciences Portfolio at Medtronic. “I’m thrilled to have him join this team as Neuromodulation moves into the era of personalized medicine with sensing technology. He will play a key role in advancing our capabilities in these areas while driving business execution in alignment with Medtronic’s focus on a performance-driven culture.”

The Neuromodulation business is part of the Neurosciences Portfolio at Medtronic and is comprised of Pain Interventions and Brain Modulation, which engineer innovative therapies and technologies to help patients relieve pain, restore function, and reclaim movement.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit Medtronic.com, and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.